Gene regulatory network analysis supports inflammation as a key neurodegeneration process in prion disease

BMC Systems Biology

Volumn 6, Issue , 2012, Pages

  Crespo, Isaac ^a   Roomp, Kirsten ^a   Jurkowski, Wiktor ^a   Kitano, Hiroaki ^b   del Sol, Antonio ^a  

^a UNIVERSITY OF LUXEMBOURG   (Luxembourg)

^b Systems Biology Institute   (Japan)

Author keywords

Gene regulatory network; Inflammation; Neurodegeneration; Perturbation; Prion disease; Stable states

Indexed keywords

ANIMAL; ARTICLE; CELL DEATH; DISEASE COURSE; GENE REGULATORY NETWORK; GENETICS; INFLAMMATION; MOUSE; NERVE CELL; PATHOLOGY; PRION DISEASE; SYSTEMS BIOLOGY;

ANIMALS; CELL DEATH; DISEASE PROGRESSION; GENE REGULATORY NETWORKS; INFLAMMATION; MICE; NEURONS; PRION DISEASES; SYSTEMS BIOLOGY;

MLCS; MLOWN;

EID: 84867352718     PISSN: None     EISSN: 17520509     Source Type: Journal    
DOI: 10.1186/1752-0509-6-132     Document Type: Article

References (56)

1. Colby DW, Prusiner SB. Prions. Cold Spring Harbor perspectives in biology 2011, 3:a006833. 10.1101/cshperspect.a006833, 3003464, 21421910.
2. Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci 2003, 4:49-60. 10.1038/nrn1007, 12511861.
3. Soto C, Satani N. The intricate mechanisms of neurodegeneration in prion diseases. Trends in molecular medicine 2010, 17:14-24.
4. Hwang D, Lee IY, Yoo H, Gehlenborg N, Cho JH, et al. A systems approach to prion disease. Mol Syst Biol 2009, 5:252. 2671916, 19308092.
5. Lucin KM, Wyss-Coray T. Immune activation in brain aging and neurodegeneration: too much or too little?. Neuron 2009, 64:110-122. 10.1016/j.neuron.2009.08.039, 2834890, 19840553.
6. Amor S, Puentes F, Baker D, van der Valk P. Inflammation in neurodegenerative diseases. Immunology 2010, 129:154-169. 10.1111/j.1365-2567.2009.03225.x, 2814458, 20561356.
7. Hughes MM, Field RH, Perry VH, Murray CL, Cunningham C. Microglia in the degenerating brain are capable of phagocytosis of beads and of apoptotic cells, but do not efficiently remove PrPSc, even upon LPS stimulation. Glia 2010, 58:2017-2030. 10.1002/glia.21070, 3498730, 20878768.
8. Rezaie P, Lantos PL. Microglia and the pathogenesis of spongiform encephalopathies. Brain Res Brain Res Rev 2001, 35:55-72. 10.1016/S0165-0173(01)00042-X, 11245886.
9. Wojtera M, Sikorska B, Sobow T, Liberski PP. Microglial cells in neurodegenerative disorders. Folia Neuropathol 2005, 43:311-321.
10. Williams A, Lucassen PJ, Ritchie D, Bruce M. PrP deposition, microglial activation, and neuronal apoptosis in murine scrapie. Exp Neurol 1997, 144:433-438. 10.1006/exnr.1997.6424, 9168844.
11. Moes M, Le Bechec A, Crespo I, Laurini C, Halavatyi A, et al. A novel network integrating a miRNA-203/SNAI1 feedback loop which regulates epithelial to mesenchymal transition. PLoS One 2012, 7:e35440. 10.1371/journal.pone.0035440, 3325969, 22514743.
12. Shiraishi T, Matsuyama S, Kitano H. Large-scale analysis of network bistability for human cancers. PLoS Comput Biol 2010, 6:e1000851. 10.1371/journal.pcbi.1000851, 2900289, 20628618.
13. Sanz J, Cozzo E, Borge-Holthoefer J, Moreno Y. Topological effects of data incompleteness of gene regulatory networks. BMC Syst Biol 2012, 6:110. 10.1186/1752-0509-6-110, 3543246, 22920968.
14. de Silva E, Thorne T, Ingram P, Agrafioti I, Swire J, et al. The effects of incomplete protein interaction data on structural and evolutionary inferences. BMC Biol 2006, 4:39. 10.1186/1741-7007-4-39, 1665463, 17081312.
15. Soto C, Satani N. The intricate mechanisms of neurodegeneration in prion diseases. Trends Mol Med 2010, 17:14-24.
16. Pirot P, Eizirik DL, Cardozo AK. Interferon-gamma potentiates endoplasmic reticulum stress-induced death by reducing pancreatic beta cell defence mechanisms. Diabetologia 2006, 49:1229-1236. 10.1007/s00125-006-0214-7, 16604358.
17. Malhotra JD, Kaufman RJ. The endoplasmic reticulum and the unfolded protein response. Semin Cell Dev Biol 2007, 18:716-731. 10.1016/j.semcdb.2007.09.003, 2706143, 18023214.
18. Kim I, Xu W, Reed JC. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov 2008, 7:1013-1030. 10.1038/nrd2755, 19043451.
19. Opazo C, Barria MI, Ruiz FH, Inestrosa NC. Copper reduction by copper binding proteins and its relation to neurodegenerative diseases. Biometals: an international journal on the role of metal ions in biology, biochemistry, and medicine 2003, 16:91-98.
20. Singh N, Singh A, Das D, Mohan ML. Redox control of prion and disease pathogenesis. Antioxid Redox Signal 2010, 12:1271-1294. 10.1089/ars.2009.2628, 2864664, 19803746.
21. Aguzzi A, Calella AM. Prions: protein aggregation and infectious diseases. Physiol Rev 2009, 89:1105-1152. 10.1152/physrev.00006.2009, 19789378.
22. Tengku-Muhammad TS, Hughes TR, Ranki H, Cryer A, Ramji DP. Differential regulation of macrophage CCAAT-enhancer binding protein isoforms by lipopolysaccharide and cytokines. Cytokine 2000, 12:1430-1436. 10.1006/cyto.2000.0711, 10976009.
23. Xu Y, Saegusa C, Schehr A, Grant S, Whitsett JA, et al. C/EBP{alpha} is required for pulmonary cytoprotection during hyperoxia. Am J Physiol Lung Cell Mol Physiol 2009, 297:L286-L298. 10.1152/ajplung.00094.2009, 2742785, 19465518.
24. Li R, Strohmeyer R, Liang Z, Lue LF, Rogers J. CCAAT/enhancer binding protein delta (C/EBPdelta) expression and elevation in Alzheimer's disease. Neurobiol Aging 2004, 25:991-999. 10.1016/j.neurobiolaging.2003.10.016, 15212823.
25. Sorensen G, Medina S, Parchaliuk D, Phillipson C, Robertson C, et al. Comprehensive transcriptional profiling of prion infection in mouse models reveals networks of responsive genes. BMC Genomics 2008, 9:114. 10.1186/1471-2164-9-114, 2294129, 18315872.
26. Hamilton JA, Whitty G, White AR, Jobling MF, Thompson A, et al. Alzheimer's disease amyloid beta and prion protein amyloidogenic peptides promote macrophage survival, DNA synthesis and enhanced proliferative response to CSF-1 (M-CSF). Brain Res 2002, 940:49-54. 10.1016/S0006-8993(02)02589-1, 12020874.
27. Bate C, Boshuizen R, Williams A. Microglial cells kill prion-damaged neurons in vitro by a CD14-dependent process. J Neuroimmunol 2005, 170:62-70. 10.1016/j.jneuroim.2005.08.021, 16225933.
28. Konno T, Morii T, Hirata A, Sato S, Oiki S, et al. Covalent blocking of fibril formation and aggregation of intracellular amyloidgenic proteins by transglutaminase-catalyzed intramolecular cross-linking. Biochemistry 2005, 44:2072-2079. 10.1021/bi047722d, 15697232.
29. Iismaa SE, Mearns BM, Lorand L, Graham RM. Transglutaminases and disease: lessons from genetically engineered mouse models and inherited disorders. Physiol Rev 2009, 89:991-1023. 10.1152/physrev.00044.2008, 19584319.
30. Minami M, Satoh M. Role of chemokines in ischemic neuronal stress. Neuromolecular Med 2005, 7:149-155. 10.1385/NMM:7:1-2:149, 16052043.
31. AstraZeneca Thiazolopyrimidine derivatives and use thereof as antagonists of the cx3cr1 receptor AstraZeneca AB 2007, Sverker Hanson, Gunnar Nordvall, AstraZeneca.
32. Cunningham C, Boche D, Perry VH. Transforming growth factor beta1, the dominant cytokine in murine prion disease: influence on inflammatory cytokine synthesis and alteration of vascular extracellular matrix. Neuropathol Appl Neurobiol 2002, 28:107-119. 10.1046/j.1365-2990.2002.00383.x, 11972797.
33. Goh AX, Li C, Sy MS, Wong BS. Altered prion protein glycosylation in the aging mouse brain. J Neurochem 2007, 100:841-854. 10.1111/j.1471-4159.2006.04268.x, 17144900.
34. Spudich A, Frigg R, Kilic E, Kilic U, Oesch B, et al. Aggravation of ischemic brain injury by prion protein deficiency: role of ERK-1/-2 and STAT-1. Neurobiol Dis 2005, 20:442-449. 10.1016/j.nbd.2005.04.002, 15893468.
35. Frigg R, Wenzel A, Samardzija M, Oesch B, Wariwoda H, et al. The prion protein is neuroprotective against retinal degeneration in vivo. Exp Eye Res 2006, 83:1350-1358. 10.1016/j.exer.2006.07.010, 16952355.
36. Hashimoto Y, Suzuki H, Aiso S, Niikura T, Nishimoto I, et al. Involvement of tyrosine kinases and STAT3 in Humanin-mediated neuroprotection. Life Sci 2005, 77:3092-3104. 10.1016/j.lfs.2005.03.031, 16005025.
37. Sponne I, Fifre A, Koziel V, Kriem B, Oster T, et al. Humanin rescues cortical neurons from prion-peptide-induced apoptosis. Mol Cell Neurosci 2004, 25:95-102. 10.1016/j.mcn.2003.09.017, 14962743.
38. Khoo JJ, Forster S, Mansell A. Toll-like receptors as interferon-regulated genes and their role in disease. Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research 2011, 31:13-25. 10.1089/jir.2010.0095, 23516500.
39. Zeytun A, van Velkinburgh JC, Pardington PE, Cary RR, Gupta G. Pathogen-specific innate immune response. Advances in experimental medicine and biology 2007, 598:342-357. 10.1007/978-0-387-71767-8_24, 17892223.
40. Trudler D, Farfara D, Frenkel D. Toll-like receptors expression and signaling in glia cells in neuro-amyloidogenic diseases: towards future therapeutic application. Mediators Inflamm 2010, 497987:12.
41. Hennessy EJ, Parker AE, O'Neill LA. Targeting toll-like receptors: emerging therapeutics?. Nature reviews Drug discovery 2010, 9:293-307. 10.1038/nrd3203, 20380038.
42. Babior BM, Lambeth JD, Nauseef W. The neutrophil NADPH oxidase. Arch Biochem Biophys 2002, 397:342-344. 10.1006/abbi.2001.2642, 11795892.
43. Chong ZZ, Maiese K. The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury. Histol Histopathol 2007, 22:1251-1267. 2515712, 17647198.
44. Thams S, Oliveira A, Cullheim S. MHC class I expression and synaptic plasticity after nerve lesion. Brain Res Rev 2008, 57:265-269. 10.1016/j.brainresrev.2007.06.016, 17764750.
45. Kauffman S. A proposal for using the ensemble approach to understand genetic regulatory networks. J Theor Biol 2004, 230:581-590. 10.1016/j.jtbi.2003.12.017, 15363677.
46. Novichkova S, Egorov S, Daraselia N. MedScan, a natural language processing engine for MEDLINE abstracts. Bioinformatics 2003, 19:1699-1706. 10.1093/bioinformatics/btg207, 12967967.
47. Daraselia N, Yuryev A, Egorov S, Novichkova S, Nikitin A, et al. Extracting human protein interactions from MEDLINE using a full-sentence parser. Bioinformatics 2004, 20:604-611. 10.1093/bioinformatics/btg452, 15033866.
48. Zinovyev A, Viara E, Calzone L, Barillot E. BiNoM: a Cytoscape plugin for manipulating and analyzing biological networks. Bioinformatics 2008, 24:876-877. 10.1093/bioinformatics/btm553, 18024474.
49. Smoot ME, Ono K, Ruscheinski J, Wang PL, Ideker T. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 2011, 27:431-432. 10.1093/bioinformatics/btq675, 3031041, 21149340.
50. Di Cara A, Garg A, De Micheli G, Xenarios I, Mendoza L. Dynamic simulation of regulatory networks using SQUAD. BMC Bioinforma 2007, 8:462.
51. Garg A, Di Cara A, Xenarios I, Mendoza L, De Micheli G. Synchronous versus asynchronous modeling of gene regulatory networks. Bioinformatics 2008, 24:1917-1925. 10.1093/bioinformatics/btn336, 2519162, 18614585.
52. Garg A, Xenarios I, Mendoza L, DeMicheli G. An efficient method for dynamic analysis of gene regulatory networks and in silico gene perturbation experiments research in computational molecular biology. Lecture Notes in Computer Science, Vol. 4453 2007, 76. Springer Berlin, Heidelberg, Speed T, Huang H.
53. Mendoza L, Xenarios I. A method for the generation of standardized qualitative dynamical systems of regulatory networks. Theoretical biology & medical modelling 2006, 3:13. 10.1186/1742-4682-3-13, 23516553.
54. Newman M, Barabási AL, Watts DJ. The Structure and Dynamics of Networks 2006, Princeton University Press, Princeton, New Jersey.
55. Dobrin R, Beg QK, Barabasi AL, Oltvai ZN. Aggregation of topological motifs in the Escherichia coli transcriptional regulatory network. BMC Bioinforma 2004, 5:10.
56. Guimera R, Sales-Pardo M, Amaral LA. Classes of complex networks defined by role-to-role connectivity profiles. Nat Phys 2007, 3:63-69. 10.1038/nphys489, 2447920, 18618010.